Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Uveal Melanoma × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 25 Carcinoma, Hepatocellular 22 Colorectal Neoplasms 16 Stomach Neoplasms 13 Esophageal Squamous Cell Carcinoma 13 Esophageal Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Lung Neoplasms 8 Head and Neck Neoplasms 8 Cholangiocarcinoma 7 Uterine Cervical Neoplasms 6 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 6 Nasopharyngeal Carcinoma 6 Rectal Neoplasms 5 Recurrence 4 Pancreatic Neoplasms 4 Locally Advanced Rectal Cancer 4 Hodgkin Disease 4 Colonic Neoplasms 4 Neoplasms 3 NSCLC 3 Lymphoma, Extranodal NK-T-Cell 3 Glioblastoma 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Neoplasm, Residual 2 Melanoma 2 Lymphoma, Follicular 2

Interventions

Ipilimumab 9 pembrolizumab 6 incomplete Freund's adjuvant 6 Nivolumab 6 Dacarbazine 5 Temozolomide 4 Sunitinib 4 MART-1 Antigen 4 tebentafusp 3 sargramostim 3 montanide ISA 51 3 aflibercept 3 Paclitaxel 3 Carboplatin 3 CTLA-4 Antigen 3 Bevacizumab 3 trametinib 2 olaparib 2 lenvatinib 2 cediranib 2 Vorinostat 2 Taxes 2 Sorafenib 2 Radiosurgery 2 MAGEA3 protein, human 2 Lenalidomide 2 Interleukin-2 2 Interleukin-12 Subunit p35 2 Cyclophosphamide 2 Cisplatin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05542342 2025-05-14

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡